Evidence map›Paper›PMID 33602923›Full record

ArticleNature communications2021

Cre-Controlled CRISPR mutagenesis provides fast and easy conditional gene inactivation in zebrafish.

Stefan Hans, Daniela Zöller, Juliane Hammer, Johanna Stucke, Sandra Spieß, Gokul Kesavan, Volker Kroehne, Juan Sebastian Eguiguren, Diana Ezhkova, Andreas Petzold and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Murine Models of Obesity-Related Cancer Risk.Cancer prevention research (Philadelphia, Pa.) · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Identification ofInternational journal of molecular sciences · 2023
    Article
  17. Review
  18. Review
  19. Review
  20. Cre/eLife · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Stefan HansCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany. stefan.hans@tu-dresden.de.ORCID 0000-0003-0283-0211
Daniela ZöllerCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany.
Juliane HammerCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany.
Johanna StuckeCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany.
Sandra SpießCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany.
Gokul KesavanCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany.ORCID 0000-0002-2828-1460
Volker KroehneCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany.ORCID 0000-0002-5610-0866
Juan Sebastian EguigurenCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany.ORCID 0000-0002-8866-4316
Diana EzhkovaCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany.
Andreas PetzoldCenter for Molecular and Cellular Bioengineering (CMCB), DRESDEN-Concept Genome Center, Technische Universität Dresden, Dresden, Germany.
Andreas DahlCenter for Molecular and Cellular Bioengineering (CMCB), DRESDEN-Concept Genome Center, Technische Universität Dresden, Dresden, Germany.ORCID 0000-0002-2668-8371
Michael BrandCenter for Molecular and Cellular Bioengineering (CMCB), Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany. michael.brand@tu-dresden.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conditional gene inactivation is a powerful tool to determine gene function when constitutive mutations result in detrimental effects. The most commonly used technique to achieve conditional gene inactivation employs the Cre/loxP system and its ability to delete DNA sequences flanked by two loxP sites. However, targeting a gene with two loxP sites is time and labor consuming. Here, we show Cre-Controlled CRISPR (3C) mutagenesis to circumvent these issues. 3C relies on gRNA and Cre-dependent Cas9-GFP expression from the same transgene. Exogenous or transgenic supply of Cre results in Cas9-GFP expression and subsequent mutagenesis of the gene of interest. The recombined cells become fluorescently visible enabling their isolation and subjection to various omics techniques. Hence, 3C mutagenesis provides a valuable alternative to the production of loxP-flanked alleles. It might even enable the conditional inactivation of multiple genes simultaneously and should be applicable to other model organisms amenable to single integration transgenesis.

Indexed as

Gene SilencingAnimalsBase SequenceClustered Regularly Interspaced Short Palindromic RepeatsEyeGreen Fluorescent ProteinsIntegrasesMonophenol MonooxygenaseMutagenesisPigmentationRNA, MessengerTime FactorsTransgenesZebrafishCre recombinaseGreen Fluorescent ProteinsIntegrasesMonophenol MonooxygenaseRNA, Messenger

Identifiers

PMID33602923
PMCPMC7893016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.